Wuhan Healthgen Biotechnology (SHSE:688765) LT-Debt-to-Total-Asset: 0.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688765 Wuhan Healthgen Biotechnology Corp SHSE:688765
19 GF Score
Price ¥55.00
! 7 Warning Signs
View Full Analysis

What is Wuhan Healthgen Biotechnology LT-Debt-to-Total-Asset?

Wuhan Healthgen Biotechnology SHSE:688765 +5.40% 19 LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Wuhan Healthgen Biotechnology's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.05.

Wuhan Healthgen Biotechnology's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.05). It may suggest that Wuhan Healthgen Biotechnology is progressively becoming more dependent on debt to grow their business.

Wuhan Healthgen Biotechnology  (SHSE:688765) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Wuhan Healthgen Biotechnology LT-Debt-to-Total-Asset Related Terms

Wuhan Healthgen Biotechnology LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Wuhan Healthgen Biotechnology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Healthgen Biotechnology LT-Debt-to-Total-Asset Chart

Wuhan Healthgen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.01 0.10 0.19 0.09

Wuhan Healthgen Biotechnology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Dec19 Dec20 Dec21 Jun22 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.37 0.38 0.09 0.05
SHSE:688765
19GF Score
Wuhan Healthgen Biotechnology Corp SHSE:688765
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Healthgen Biotechnology LT-Debt-to-Total-Asset Calculation

Wuhan Healthgen Biotechnology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=313.269/3702.888
=0.08

Wuhan Healthgen Biotechnology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=168.706/3641.232
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.05 mean?
Wuhan Healthgen Biotechnology (SHSE:688765) has a LT-Debt-to-Total-Asset of 0.05 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Wuhan Healthgen Biotechnology and its competitors.
Is Wuhan Healthgen Biotechnology's LT-Debt-to-Total-Asset too high?
Wuhan Healthgen Biotechnology's current LT-Debt-to-Total-Asset is 0.05. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Wuhan Healthgen Biotechnology's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Wuhan Healthgen Biotechnology and its competitors. Wuhan Healthgen Biotechnology's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current LT-Debt-to-Total-Asset of 0.05. The current LT-Debt-to-Total-Asset is 0.05. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current LT-Debt-to-Total-Asset is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan Healthgen Biotechnology Business Description

Address No. 268, Shendun 5th Road, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430206
Wuhan Healthgen Biotechnology Corp is engaged in Research, development, production and commercialization of plant-based molecular medicines.
19GF Score

Get the complete analysis for SHSE:688765

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥55.00
Price